Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - GILEAD SCIENCES INC | a8-kq212earningspressrelea.htm |
CONTACTS: Investors Media
Robin Washington Amy Flood
(650) 522-5688 (650) 522-5643
Patrick O'Brien
(650) 522-1936
For Immediate Release
GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2012 FINANCIAL RESULTS
- Product Sales of $2.32 Billion, Up 14 Percent over Second Quarter 2011 -
- Antiviral Product Sales of $2.01 Billion, Up 14 Percent over Second Quarter of 2011 -
Foster City, CA, July 26, 2012 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the quarter ended June 30, 2012. Total revenues for the second quarter of 2012 increased 13 percent to $2.41 billion, from $2.14 billion for the second quarter of 2011. Net income for the second quarter of 2012 was $711.6 million, or $0.91 per diluted share compared to $746.2 million, or $0.93 per diluted share for the second quarter of 2011. Non-GAAP net income for the second quarter of 2012, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $767.3 million, or $0.99 per diluted share compared to $797.7 million, or $1.00 per diluted share for the second quarter of 2011.
Product Sales
Product sales increased 14 percent to $2.32 billion for the second quarter of 2012 compared to $2.04 billion for the second quarter of 2011. This increase in product sales was driven primarily by Gilead's antiviral franchise, resulting from increased sales of Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), Truvada® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and Complera®/Eviplera® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg) which was launched in the U.S. in August 2011.
Antiviral Franchise
Antiviral product sales increased 14 percent to $2.01 billion for the second quarter of 2012, up from $1.76 billion for the second quarter of 2011, reflecting sales growth of 21 percent in the U.S. and 3 percent in Europe. In the U.S., antiviral product sales for the second quarter of 2012 reflect the benefit of purchases by certain state AIDS Drug Assistance Programs (ADAPs) in excess of demand.
• | Atripla |
Sales of Atripla increased 10 percent to $904.0 million for the second quarter of 2012, up from $822.0 million for the second quarter of 2011, reflecting sales growth of 12 percent in the U.S. and 5 percent in Europe.
• | Truvada |
Sales of Truvada increased 10 percent to $785.9 million for the second quarter of 2012, up from $711.3 million for the second quarter of 2011, reflecting sales growth of 18 percent in the U.S. and 2 percent in Europe.
- more -
Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA | www.gilead.com | |
phone 650 574 3000 facsimile 650 578 9264 | ||
July 26, 2012 | Page2 | |
• | Viread |
Sales of Viread® (tenofovir disoproxil fumarate) increased 16 percent to $215.4 million for the second quarter of 2012, up from $185.7 million for the second quarter of 2011, reflecting sales growth of 27 percent in the U.S. partially offset by a decrease of 2 percent in Europe.
• | Complera/Eviplera |
Sales of Complera/Eviplera increased 40 percent to $72.9 million during the second quarter of 2012 from $52.2 million for the first quarter of 2012. Complera was approved in the U.S. in August 2011, and Eviplera was approved in the European Union in November 2011.
Letairis
Sales of Letairis® (ambrisentan) increased 38 percent to $101.6 million for the second quarter of 2012, up from $73.6 million for the second quarter of 2011.
Ranexa
Sales of Ranexa® (ranolazine) increased 11 percent to $95.6 million for the second quarter of 2012, up from $86.1 million for the second quarter of 2011.
Other Products
Sales of other products were $111.8 million for the second quarter of 2012 compared to $115.5 million for the second quarter of 2011 and included AmBisome® (amphotericin B) liposome for injection and Cayston® (aztreonam for inhalation solution).
Royalty, Contract and Other Revenues
Royalty, contract and other revenues were $83.9 million for the second quarter of 2012, down 14 percent from $97.7 million for the second quarter of 2011, due primarily to lower Tamiflu royalties from F. Hoffmann-La Roche Ltd., partially offset by an increase in other royalty revenues.
Research and Development
Research and development (R&D) expenses for the second quarter of 2012 were $396.2 million compared to $282.4 million for the second quarter of 2011. Non-GAAP R&D expenses for the second quarter of 2012, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $371.4 million compared to $262.6 million for the second quarter of 2011. The increase in non-GAAP R&D expenses was due primarily to the continued advancement of Gilead's product pipeline, particularly in the liver disease and oncology franchises.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses in the second quarter of 2012 were $332.5 million compared to $304.3 million for the second quarter of 2011. Non-GAAP SG&A expenses for the second quarter of 2012, which exclude acquisition-related, restructuring and stock-based compensation expenses, were $298.7 million compared to $276.4 million for the second quarter of 2011. The increase in non-GAAP SG&A expenses was due primarily to increased expenses to support the ongoing growth of Gilead's business.
Interest Expense and Other Income (Expense), Net
Interest expense for the second quarter of 2012 was $88.4 million compared to $46.1 million for the second quarter of 2011. The increase was due primarily to the additional debt issued in connection with the acquisition of Pharmasset Inc. (Pharmasset) in the first quarter of 2012. Other income (expense), net for the second quarter of 2012 was a net expense of $1.1 million compared to net income of $12.0 million in the second quarter of 2011. The change was due primarily to decreased interest income from lower cash, cash equivalents and marketable securities.
- more -
July 26, 2012 | Page3 | |
Net Foreign Currency Exchange Impact
The net foreign currency exchange impact on second quarter 2012 product sales and pre-tax earnings was an unfavorable $31.7 million and $17.4 million, respectively, compared to the second quarter of 2011.
Cash, Cash Equivalents and Marketable Securities
As of June 30, 2012, Gilead had $2.27 billion of cash, cash equivalents and marketable securities compared to $9.96 billion as of December 31, 2011. The decrease was due to the acquisition of Pharmasset in the first quarter of 2012. Gilead generated $1.74 billion of operating cash flow during the first six months of 2012 including $1.29 billion generated in the second quarter of 2012 driven by the collection of $460 million of past due accounts receivable in Spain contributing to a 15 day reduction in days sales outstanding.
Corporate Highlights
Antiviral Franchise
In April, Gilead announced interim data from the Phase 2 ATOMIC study examining a 12-week course of treatment with the investigational once-daily nucleotide GS-7977 plus pegylated interferon and ribavirin (RBV) in treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. The study found that 90 percent of patients achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load 12 weeks after the completion of therapy. These findings were presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain.
Also in April, Gilead announced interim data from the Phase 2 ELECTRON study examining GS-7977 plus RBV in treatment-naïve patients with genotype 1 chronic HCV infection. Of the 25 patients who completed 12 weeks of treatment, 88 percent achieved a four-week sustained virologic response (SVR4). Three patients experienced viral relapse. These findings were presented at EASL.
Lastly in April, Gilead announced interim results from the Phase 2 QUANTUM study examining a 12-week duration of GS-7977 plus RBV in treatment-naïve patients. Twenty-five patients were randomized to the 12-week treatment arm: 19 genotype 1 patients; four genotype 3 patients; and two genotype 2 patients. At the four-week post-treatment time period, data were available for 17 genotype 1 patients. Of these, 59 percent achieved SVR4 and 41 percent experienced viral relapse. Additionally, seven of the patients who reached the eight-week post-treatment time period, and who achieved SVR4, remained HCV RNA undetectable.
In May, Gilead announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to support approval of once-daily oral Truvada to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP. The Antiviral Drugs Advisory Committee also voted 13 to one in support of approval of Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults.
Also in May, Gilead announced that the Marketing Authorisation Application (MAA) for cobicistat had been validated by the European Medicines Agency (EMA). Cobicistat is Gilead's pharmacoenhancing or “boosting” agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing. In June, Gilead submitted a New Drug Application (NDA) to the FDA for marketing approval of cobicistat.
In June, Gilead announced that its NDA and MAA for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, had been submitted to the FDA and validated by the EMA, respectively. Elvitegravir, a component of Gilead's once-daily Quad single tablet regimen, is currently under U.S. and European regulatory review for treatment-naïve adult patients.
- more -
July 26, 2012 | Page4 | |
Oncology Franchise
In May, Gilead announced that the first patient had been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101 in combination with rituximab in previously treated chronic lymphocytic leukemia patients. GS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase delta isoform.
Conference Call
At 4:15 p.m. Eastern Time today, Gilead's management will host a conference call and a simultaneous webcast to discuss results from its second quarter 2012, provide an update on Gilead's full year 2012 guidance, as well as provide a general business update. To access the webcast live via the internet, please connect to the company's website at www.gilead.com 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-866-783-2140 (U.S.) or 1-857-350-1599 (international) and dial the participant passcode 60422538 to access the call.
A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through July 29, 2012. To access the phone replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 39788296.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.
Non-GAAP Financial Information
Gilead has presented certain financial information in accordance with U.S. GAAP (GAAP) and also on a non-GAAP basis for the second quarter of 2012 and 2011. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under U.S. GAAP. A reconciliation between GAAP and non-GAAP financial information is provided in the table on page 7.
- more -
July 26, 2012 | Page5 | |
Forward-looking Statements
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2012 financial results, including the possibility that its full year 2012 guidance may be revised at a later date; Gilead's ability to sustain growth in revenues for its antiviral, cardiovascular and respiratory franchises; unpredictable variability of Tamiflu royalties and the strong relationship between this royalty revenue and global pandemic planning and supply; the availability of funding for state ADAPs and their ability to purchase at levels to support the number of patients that rely on ADAPs; continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; the possibility that the proportion of patients who maintain a sustained virologic response 4 and 12 weeks post-treatment will not be as favorable as the sustained virologic response rates reported in this press release and the possibility of unfavorable results from additional arms of the ATOMIC, ELECTRON and QUANTUM studies and subsequent clinical trials involving GS-7977 and RBV and GS-7977 plus pegylated interferon and RBV; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Gilead's ability to submit NDAs and MAAs for new product candidates in the timelines currently anticipated, including GS-7977 for the treatment of HCV; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Quad, cobicistat or elvitegravir; Gilead's ability to successfully commercialize its products, including Complera/Eviplera; Gilead's ability to successfully develop its respiratory, cardiovascular and oncology franchises; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS-7977 and GS-1101; the potential for additional austerity measures in European countries that may increase the amount of discount required on Gilead's products; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; Gilead's ability to advance Pharmasset's product pipeline or develop an all-oral antiviral regimen for HCV; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market-specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and other subsequent disclosure documents filed with the Securities and Exchange Commission and press releases. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
# # #
Truvada, Viread, Hepsera, Complera, Eviplera, Emtriva, AmBisome, Letairis, Cayston, Ranexa and Volibris are
registered trademarks of Gilead Sciences, Inc.
Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Tamiflu is a registered trademark of F. Hoffmann-La Roche Ltd.
For more information on Gilead Sciences, Inc., please visit www.gilead.com or
call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
- more -
July 26, 2012 | Page6 | |
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(in thousands, except per share amounts)
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||
Revenues: | ||||||||||||||||
Product sales | $ | 2,321,240 | $ | 2,039,588 | $ | 4,529,582 | $ | 3,903,166 | ||||||||
Royalty, contract and other revenues | 83,946 | 97,665 | 158,053 | 160,181 | ||||||||||||
Total revenues | 2,405,186 | 2,137,253 | 4,687,635 | 4,063,347 | ||||||||||||
Costs and expenses: | ||||||||||||||||
Cost of goods sold | 617,345 | 533,863 | 1,198,276 | 1,007,974 | ||||||||||||
Research and development | 396,244 | 282,403 | 854,455 | 536,849 | ||||||||||||
Selling, general and administrative | 332,505 | 304,269 | 775,626 | 599,837 | ||||||||||||
Total costs and expenses | 1,346,094 | 1,120,535 | 2,828,357 | 2,144,660 | ||||||||||||
Income from operations | 1,059,092 | 1,016,718 | 1,859,278 | 1,918,687 | ||||||||||||
Interest expense | (88,418 | ) | (46,107 | ) | (185,688 | ) | (87,323 | ) | ||||||||
Other income (expense), net | (1,075 | ) | 11,978 | (35,160 | ) | 25,810 | ||||||||||
Income before provision for income taxes | 969,599 | 982,589 | 1,638,430 | 1,857,174 | ||||||||||||
Provision for income taxes | 263,525 | 240,130 | 494,825 | 467,412 | ||||||||||||
Net income | 706,074 | 742,459 | 1,143,605 | 1,389,762 | ||||||||||||
Net loss attributable to noncontrolling interest | 5,490 | 3,768 | 9,915 | 7,606 | ||||||||||||
Net income attributable to Gilead | $ | 711,564 | $ | 746,227 | $ | 1,153,520 | $ | 1,397,368 | ||||||||
Net income per share attributable to Gilead common stockholders - basic | $ | 0.94 | $ | 0.95 | $ | 1.52 | $ | 1.77 | ||||||||
Net income per share attributable to Gilead common stockholders - diluted | $ | 0.91 | $ | 0.93 | $ | 1.48 | $ | 1.73 | ||||||||
Shares used in per share calculation - basic | 756,951 | 784,807 | 756,619 | 790,430 | ||||||||||||
Shares used in per share calculation - diluted | 780,506 | 800,800 | 779,246 | 806,462 | ||||||||||||
July 26, 2012 | Page7 | |
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)
(in thousands, except percentages and per share amounts)
Three Months Ended | Six Months Ended | ||||||||||||||
June 30, | June 30, | ||||||||||||||
2012 | 2011 | 2012 | 2011 | ||||||||||||
Cost of goods sold reconciliation: | |||||||||||||||
GAAP cost of goods sold | $ | 617,345 | $ | 533,863 | $ | 1,198,276 | $ | 1,007,974 | |||||||
Stock-based compensation expenses | (2,119 | ) | (2,887 | ) | (4,220 | ) | (5,531 | ) | |||||||
Acquisition related-amortization of purchased intangibles | (15,836 | ) | (17,408 | ) | (31,672 | ) | (34,815 | ) | |||||||
Non-GAAP cost of goods sold | $ | 599,390 | $ | 513,568 | $ | 1,162,384 | $ | 967,628 | |||||||
Product gross margin reconciliation: | |||||||||||||||
GAAP product gross margin | 73.5 | % | 73.9 | % | 73.6 | % | 74.2 | % | |||||||
Stock-based compensation expenses | 0.1 | % | 0.1 | % | 0.1 | % | 0.1 | % | |||||||
Acquisition related-amortization of purchased intangibles | 0.7 | % | 0.9 | % | 0.7 | % | 0.9 | % | |||||||
Non-GAAP product gross margin(1) | 74.3 | % | 74.9 | % | 74.4 | % | 75.3 | % | |||||||
Research and development expenses reconciliation: | |||||||||||||||
GAAP research and development expenses | $ | 396,244 | $ | 282,403 | $ | 854,455 | $ | 536,849 | |||||||
Stock-based compensation expenses | (20,355 | ) | (19,420 | ) | (138,978 | ) | (36,140 | ) | |||||||
Restructuring expenses | (1,576 | ) | (767 | ) | (7,090 | ) | (554 | ) | |||||||
Acquisition related-transaction costs | (345 | ) | — | (345 | ) | (446 | ) | ||||||||
Acquisition related-contingent consideration remeasurement | (2,570 | ) | 418 | (5,306 | ) | 418 | |||||||||
Non-GAAP research and development expenses | $ | 371,398 | $ | 262,634 | $ | 702,736 | $ | 500,127 | |||||||
Selling, general and administrative expenses reconciliation: | |||||||||||||||
GAAP selling, general and administrative expenses | $ | 332,505 | $ | 304,269 | $ | 775,626 | $ | 599,837 | |||||||
Stock-based compensation expenses | (25,929 | ) | (27,818 | ) | (147,873 | ) | (57,924 | ) | |||||||
Restructuring expenses | (7,251 | ) | 353 | (10,407 | ) | (1,666 | ) | ||||||||
Acquisition related-transaction costs | (594 | ) | (365 | ) | (10,874 | ) | (743 | ) | |||||||
Non-GAAP selling, general and administrative expenses | $ | 298,731 | $ | 276,439 | $ | 606,472 | $ | 539,504 | |||||||
Operating margin reconciliation: | |||||||||||||||
GAAP operating margin | 44.0 | % | 47.6 | % | 39.7 | % | 47.2 | % | |||||||
Stock-based compensation expenses | 2.0 | % | 2.3 | % | 6.2 | % | 2.5 | % | |||||||
Restructuring expenses | 0.4 | % | 0.0 | % | 0.4 | % | 0.1 | % | |||||||
Acquisition related-transaction costs | — | % | 0.0 | % | 0.2 | % | 0.0 | % | |||||||
Acquisition related-amortization of purchased intangibles | 0.7 | % | 0.8 | % | 0.7 | % | 0.9 | % | |||||||
Acquisition related-contingent consideration remeasurement | 0.1 | % | — | 0.1 | % | 0.0 | % | ||||||||
Non-GAAP operating margin(1) | 47.2 | % | 50.7 | % | 47.3 | % | 50.6 | % | |||||||
Interest expense reconciliation: | |||||||||||||||
GAAP interest expense | $ | (88,418 | ) | $ | (46,107 | ) | $ | (185,688 | ) | $ | (87,323 | ) | |||
Acquisition related-transaction costs | — | — | 7,333 | — | |||||||||||
Non-GAAP interest expense | $ | (88,418 | ) | $ | (46,107 | ) | $ | (178,355 | ) | $ | (87,323 | ) | |||
Net income attributable to Gilead reconciliation: | |||||||||||||||
GAAP net income attributable to Gilead, net of tax | $ | 711,564 | $ | 746,227 | $ | 1,153,520 | $ | 1,397,368 | |||||||
Stock-based compensation expenses | 35,236 | 37,915 | 264,840 | 74,529 | |||||||||||
Restructuring expenses | 6,426 | 324 | 12,772 | 1,661 | |||||||||||
Acquisition related-transaction costs | 651 | 365 | 13,542 | 1,189 | |||||||||||
Acquisition related-amortization of purchased intangibles | 11,529 | 13,170 | 23,119 | 26,053 | |||||||||||
Acquisition related-contingent consideration remeasurement | 1,871 | (313 | ) | 3,873 | (313 | ) | |||||||||
Non-GAAP net income attributable to Gilead, net of tax | $ | 767,277 | $ | 797,688 | $ | 1,471,666 | $ | 1,500,487 | |||||||
Diluted earnings per share reconciliation: | |||||||||||||||
GAAP diluted earnings per share | $ | 0.91 | $ | 0.93 | $ | 1.48 | $ | 1.73 | |||||||
Stock-based compensation expenses | 0.05 | 0.05 | 0.34 | 0.09 | |||||||||||
Restructuring expenses | 0.01 | — | 0.02 | — | |||||||||||
Acquisition related-transaction costs | — | 0.00 | 0.02 | 0.00 | |||||||||||
Acquisition related-amortization of purchased intangibles | 0.01 | 0.02 | 0.03 | 0.03 | |||||||||||
Acquisition related-contingent consideration remeasurement | 0.00 | (0.00) | — | (0.00) | |||||||||||
Non-GAAP diluted earnings per share(1) | $ | 0.99 | $ | 1.00 | $ | 1.89 | $ | 1.87 | |||||||
Shares used in per share calculation (diluted) reconciliation: | |||||||||||||||
GAAP shares used in per share calculation (diluted) | 780,506 | 800,800 | 779,246 | 806,462 | |||||||||||
Share impact of current stock-based compensation rules | (1,573 | ) | (2,010 | ) | (1,671 | ) | (1,993 | ) | |||||||
Non-GAAP shares used in per share calculation (diluted) | 778,933 | 798,790 | 777,575 | 804,469 | |||||||||||
Non-GAAP adjustment summary: | |||||||||||||||
Cost of goods sold adjustments | $ | 17,955 | $ | 20,295 | $ | 35,892 | $ | 40,346 | |||||||
Research and development expenses adjustments | 24,846 | 19,769 | 151,719 | 36,722 | |||||||||||
Selling, general and administrative expenses adjustments | 33,774 | 27,830 | 169,154 | 60,333 | |||||||||||
Interest expense adjustments | — | — | 7,333 | — | |||||||||||
Total non-GAAP adjustments before tax | 76,575 | 67,894 | 364,098 | 137,401 | |||||||||||
Income tax effect | (20,862 | ) | (16,433 | ) | (45,952 | ) | (34,282 | ) | |||||||
Total non-GAAP adjustments after tax | $ | 55,713 | $ | 51,461 | $ | 318,146 | $ | 103,119 | |||||||
Note: | |||||||||||||||
(1) Amounts may not sum due to rounding | |||||||||||||||
July 26, 2012 | Page8 | |
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
June 30, | December 31, | ||||||
2012 | 2011 | ||||||
(unaudited) | (Note 1) | ||||||
Cash, cash equivalents and marketable securities | $ | 2,271,674 | $ | 9,963,972 | |||
Accounts receivable, net | 1,702,818 | 1,951,167 | |||||
Inventories | 1,603,401 | 1,389,983 | |||||
Property, plant and equipment, net | 811,799 | 774,406 | |||||
Intangible assets, net | 11,751,191 | 1,062,864 | |||||
Goodwill | 1,078,919 | 1,004,102 | |||||
Other assets | 1,282,148 | 1,156,640 | |||||
Total assets | $ | 20,501,950 | $ | 17,303,134 | |||
Current liabilities | $ | 4,986,674 | $ | 2,514,790 | |||
Long-term liabilities | 7,431,889 | 7,920,995 | |||||
Stockholders’ equity (Note 2) | 8,083,387 | 6,867,349 | |||||
Total liabilities and stockholders’ equity | $ | 20,501,950 | $ | 17,303,134 | |||
Notes: |
(1) Derived from the audited consolidated financial statements as of December 31, 2011. |
(2) As of June 30, 2012, there were 756,153 shares of common stock issued and outstanding. |
July 26, 2012 | Page9 | |
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
(in thousands)
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||
Antiviral products: | ||||||||||||||||
Atripla – U.S. | $ | 570,835 | $ | 510,237 | $ | 1,132,879 | $ | 973,004 | ||||||||
Atripla – Europe | 280,125 | 267,153 | 550,821 | 520,210 | ||||||||||||
Atripla – Other International | 53,063 | 44,602 | 107,919 | 73,290 | ||||||||||||
904,023 | 821,992 | 1,791,619 | 1,566,504 | |||||||||||||
Truvada – U.S. | 393,013 | 334,064 | 766,339 | 654,177 | ||||||||||||
Truvada – Europe | 328,814 | 322,007 | 650,690 | 621,163 | ||||||||||||
Truvada – Other International | 64,106 | 55,230 | 127,167 | 109,072 | ||||||||||||
785,933 | 711,301 | 1,544,196 | 1,384,412 | |||||||||||||
Viread – U.S. | 102,112 | 80,228 | 183,768 | 152,708 | ||||||||||||
Viread – Europe | 84,108 | 86,123 | 168,993 | 162,135 | ||||||||||||
Viread – Other International | 29,194 | 19,366 | 54,346 | 39,269 | ||||||||||||
215,414 | 185,717 | 407,107 | 354,112 | |||||||||||||
Complera / Eviplera – U.S. | 65,004 | — | 113,643 | — | ||||||||||||
Complera / Eviplera – Europe | 7,198 | — | 10,465 | — | ||||||||||||
Complera / Eviplera – Other International | 707 | — | 981 | — | ||||||||||||
72,909 | — | 125,089 | — | |||||||||||||
Hepsera – U.S. | 8,172 | 14,765 | 20,981 | 28,639 | ||||||||||||
Hepsera – Europe | 15,420 | 20,582 | 29,385 | 42,070 | ||||||||||||
Hepsera – Other International | 2,599 | 3,309 | 5,122 | 6,043 | ||||||||||||
26,191 | 38,656 | 55,488 | 76,752 | |||||||||||||
Emtriva – U.S. | 4,770 | 3,914 | 8,863 | 7,816 | ||||||||||||
Emtriva – Europe | 1,741 | 1,705 | 3,552 | 3,390 | ||||||||||||
Emtriva – Other International | 1,302 | 1,113 | 2,175 | 2,102 | ||||||||||||
7,813 | 6,732 | 14,590 | 13,308 | |||||||||||||
Total Antiviral products – U.S. | 1,143,906 | 943,208 | 2,226,473 | 1,816,344 | ||||||||||||
Total Antiviral products – Europe | 717,406 | 697,570 | 1,413,906 | 1,348,968 | ||||||||||||
Total Antiviral products – Other International | 150,971 | 123,620 | 297,710 | 229,776 | ||||||||||||
2,012,283 | 1,764,398 | 3,938,089 | 3,395,088 | |||||||||||||
AmBisome | 83,653 | 88,625 | 168,417 | 167,131 | ||||||||||||
Letairis | 101,634 | 73,637 | 188,922 | 135,811 | ||||||||||||
Ranexa | 95,555 | 86,077 | 178,756 | 154,370 | ||||||||||||
Other products | 28,115 | 26,851 | 55,398 | 50,766 | ||||||||||||
308,957 | 275,190 | 591,493 | 508,078 | |||||||||||||
Total product sales | $ | 2,321,240 | $ | 2,039,588 | $ | 4,529,582 | $ | 3,903,166 | ||||||||